| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.207.294 |
| Chemical and physical data | |
| Formula | C20H21NO |
| Molar mass | 291.394 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
PRC200-SS is an experimental drug of thetriple reuptake inhibitor class that was investigated by theMayo Clinic.[1][2]
Preclinical toxicology studies of PRC200-SS incynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any furtherdrug development.